Ligand Pharmaceuticals

Quarterly Financials

Values in thousands 2024-06-30 2024-03-31 2023-12-31 2023-09-30
Revenue
$41,531
$30,978
$28,101
$32,868
Gross Profit
30,368
19,910
26,437
29,383
EBITDA
16,748
12,231
9,874
23,458
EBIT
7,391
2,988
444
14,582
Net Income
-51,911
86,139
18,188
-12,792
Net Change In Cash
41,531
30,978
28,101
32,868
Free Cash Flow
11,118
18,586
-42,680
7,159
Cash
18,139
50,093
22,954
19,275
Basic Shares
18,028
18,122
17,676
17,380

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$131,314
$196,245
$277,133
$186,419
Gross Profit
119,753
143,418
214,957
156,000
EBITDA
51,223
8,734
117,202
31,992
EBIT
13,812
-34,660
75,865
4,026
Net Income
52,154
-5,219
57,138
-2,985
Net Change In Cash
131,314
196,245
277,133
186,419
Cost of Revenue
-28,440
-24,311
Free Cash Flow
-4,272
119,927
70,037
50,128
Cash
22,954
45
19,522
47,619
Basic Shares
17,757
16,868
17,246
16,184

Earnings Calls

Quarter EPS
2024-06-30
$1.40
2024-03-31
$1.20
2023-12-31
$1.38
2023-09-30
$1.02